Henrietta Lacks: Born Loretta Pleasant, Her Cells Changed Medicine—But She Never Gave Permission
By Renee Whitley, Writer
October 12, 2026
Image source: Internet.
Henrietta Lacks entered a hospital seeking treatment for cancer. She could not have known that cells taken from her body would become one of the most important tools in medical research—or that generations of her family would fight to have her humanity recognized alongside her scientific legacy.
Born Loretta Pleasant, Henrietta was a Black woman, a wife, and a mother of five. She died in 1951 at just 31 years old. Yet descendants of her cancer cells continue to grow in laboratories, helping researchers investigate diseases and develop medical advances. The cells were collected and used without her knowledge or consent. www.genome.gov
Her story deserves renewed attention because the questions it raises are still with us: Who gets to make decisions about a person’s body? Who benefits when biological material becomes commercially valuable? And what does justice require when scientific progress begins with someone being denied a choice?
Before HeLa, there was Loretta Pleasant
Henrietta Lacks was born Loretta Pleasant on August 1, 1920, in Roanoke, Virginia. Later known as Henrietta, she married David “Day” Lacks on April 10, 1941. They became parents to five children and lived in the Baltimore area. www.genome.gov
Her life unfolded in an America shaped by racial segregation and unequal access to opportunities, including medical care. When she sought treatment at Johns Hopkins Hospital in 1951, it was among the few hospitals in the region that treated poor African American patients. www.hopkinsmedicine.org
Remembering these details helps restore the person behind the laboratory name. Henrietta had a family, responsibilities, and a future that cancer cut short. Her importance did not begin when researchers discovered that her cells could survive outside her body.
What happened when she sought treatment
In 1951, Henrietta went to Johns Hopkins Hospital after experiencing vaginal bleeding. Doctors discovered a malignant tumor on her cervix, and she began receiving radium treatment for cervical cancer. During her care, tumor tissue was collected and sent to the laboratory of researcher George Gey. www.hopkinsmedicine.org
Henrietta had signed a form authorizing medical treatment. According to Johns Hopkins, that form did not mention research, and she never knew her cells had been collected for that purpose. She had no informed opportunity to decide whether she wanted her tissue used in scientific experiments. www.hopkinsmedicine.org
Johns Hopkins explains that collecting extra tissue for research without obtaining permission was common practice at the time, including from cervical cancer patients across racial and economic backgrounds. That explains the institutional practice. It does not erase the ethical failure to give Henrietta information and a choice. www.hopkinsmedicine.org
Despite treatment, her cancer progressed. She died on October 4, 1951, leaving behind her husband and five children. She was 31. www.hopkinsmedicine.org
The cells that kept growing
Researchers had struggled to maintain human cells in laboratories because most samples died relatively quickly. Henrietta’s cancer cells behaved differently: they continued growing and dividing.
They became the first human cell line successfully maintained for continuous research. Scientists named them HeLa, using the first letters of Henrietta and Lacks. www.hopkinsmedicine.org
The description “immortal” refers to the cell line’s ability to keep reproducing under suitable laboratory conditions. It does not mean Henrietta survived her illness or that every individual cell lives forever.
Having a dependable supply of human cells allowed scientists to repeat experiments and share research materials. Researchers could investigate biological processes and study how cells responded to infections, radiation, drugs, and other substances. apnews.com
HeLa cells contributed to research supporting the polio vaccine, studies of cancer and HIV, investigations into how human papillomavirus—HPV—causes cancer, and critical COVID-19 research. They have also been used to study conditions in space. These contributions were part of larger scientific efforts involving many researchers and methods. www.genome.gov
The scientific value was extraordinary. Henrietta’s exclusion from decisions about that research was equally significant.
Her family was left outside the story
While HeLa cells became increasingly important to science, Henrietta’s family was not informed of their role in major medical advances. Johns Hopkins acknowledges that failure to communicate. www.hopkinsmedicine.org
For relatives grieving a wife and mother, the existence of a continuing cell line was more than a scientific fact. It connected their personal loss to a worldwide research enterprise in which they had been given little information or influence.
Rebecca Skloot’s 2010 book, The Immortal Life of Henrietta Lacks, brought the story to a much wider audience. It helped shift public attention toward Henrietta’s life and the consequences for her family. osp.od.nih.gov
The language used to describe her matters. Calling Henrietta a “donor” without explaining the circumstances can suggest that she voluntarily offered her cells. She did not give that permission.
Her contribution should be recognized without rewriting the conditions under which it occurred.
Scientific benefit and commercial profit
The financial history requires a careful distinction.
Johns Hopkins states that it never sold or profited from the discovery or distribution of HeLa cells and that it shared them freely for scientific research. Later commercialization by biotechnology and pharmaceutical companies became the focus of lawsuits brought by Henrietta’s estate. www.hopkinsmedicine.org
The estate’s legal actions raise questions about whether companies unjustly benefited from material obtained without her consent. Those allegations concern later commercial conduct, rather than a claim that every researcher or institution using HeLa profited in the same way.
At the center of the dispute is a question that scientific achievement alone cannot answer: What responsibility do businesses have to the person and family behind a valuable biological resource?
Another chapter: genetic privacy
In 2013, researchers published information about the HeLa genome, raising concerns about the privacy of Henrietta’s descendants. Genetic information from the cell line could potentially reveal information relevant to family members, including possible disease risks. osp.od.nih.gov
The controversy demonstrated how decisions about biological material can affect relatives long after the original patient has died.
That year, the National Institutes of Health reached an agreement with the Lacks family establishing controlled access to specified HeLa whole-genome sequence data. Family members participate in the group reviewing access requests. NIH reaffirmed the partnership in 2023 and later clarified its expectations for researchers. www.grants.nih.gov
The agreement gave the family a meaningful voice in decisions involving covered genomic data. Its scope is limited: it does not give the family authority over every HeLa experiment or commercial use around the world.
Why we should revisit her story now
October 4, 2026, marked 75 years since Henrietta Lacks died. Her family’s pursuit of accountability also produced new developments this year.
Her estate resolved its lawsuit against Thermo Fisher Scientific in 2023. A confidential settlement with Novartis followed in February 2026, and litigation with Viatris was resolved in March 2026. The estate’s attorneys report that litigation against Ultragenyx remains active. The settlement terms have not been publicly disclosed. www.seegerweiss.com
These agreements are settlements, rather than court verdicts establishing every allegation. They show, however, that questions about commercial benefit and accountability remain active generations after Henrietta’s tissue was collected.
International recognition has grown as well. In 2021, the World Health Organization honored Henrietta with a posthumous award acknowledging her contribution to medical science and the injustice surrounding her story. In 2022, members of her family became WHO Goodwill Ambassadors for Cervical Cancer Elimination. www.who.int
Recognition can help restore a name and a history. It should also encourage institutions to examine how they treat patients and families today.
What her story teaches about consent and trust
Henrietta’s experience exposes a profound imbalance: a person’s body can become enormously valuable to research while that person has little power over its use.
For Black women, her history invites serious conversations about race, gender, access to care, and whose voice carries authority in medical settings. Institutions earn trust through clear explanations, respectful treatment, meaningful patient participation, and accountability.
Modern research protections differ substantially from those in 1951. Federal rules establish requirements for informed consent and ethics review in covered human-subjects research. However, it would be inaccurate to claim that every research use of human tissue now requires a new consent form. Under the Common Rule, research using nonidentified biospecimens can fall outside the definition of human-subjects research. www.hhs.gov
That distinction makes transparency especially important. Patients should be able to understand how their samples and information may be used. Applicable consent requirements include certain disclosures about possible commercial profit and whether participants will share in it. www.hhs.gov
Meaningful consent requires more than a signature. People need understandable information, an opportunity to ask questions, and a real ability to decide.
Remembering the whole woman
Bringing Henrietta Lacks’ story back to the forefront means teaching it in classrooms, discussing it in medical training, and including it when scientific progress is celebrated.
It means remembering Loretta Pleasant, the girl who became Henrietta Lacks, alongside the mother whose life ended far too soon. It also means listening to the descendants who have worked to protect her legacy and participate in decisions affecting their family.
Her story asks us to examine scientific achievement together with the conditions that made it possible. Medical progress carries a responsibility to respect the people behind the discoveries.
Henrietta’s cells became known around the world. Her name, her life, and her right to have been asked deserve the same recognition.
About the Author
Renee Whitley, known publicly as Miss Hollywood, is a writer, author, media host, producer, filmmaker, and songwriter based in Philadelphia. Through her platform, The Chat with Miss Hollywood, she explores stories spanning culture, entertainment, history, and the human experience.
Her work encourages honest conversations and brings attention to people and experiences that deserve to be heard. In revisiting Henrietta Lacks’ story, Renee highlights the importance of remembering the woman behind the scientific legacy—and keeping dignity, consent, and accountability at the center of that conversation.
Explore more at thechatwithmisshollywood.com.
Why Her Story Matters
Remembering Henrietta Lacks means recognizing the woman behind HeLa—and insisting that scientific progress comes with respect for human dignity. Her story reminds us to ask questions, understand what we are consenting to, and expect clear answers about our care.
Share her story. Say her name. Make sure the next generation knows who Henrietta Lacks was and why her life matters.
A Special Thank You
A heartfelt thank you to my friend Jo Smith, who first brought Henrietta Lacks’ story to my attention a couple of years ago. I was utterly shocked by what I learned, and I have never forgotten it. Jo is such a smart and knowledgeable person, and I’m grateful she shared this history with me. Thank you, Jo, for inspiring me to learn more—and ultimately share Henrietta’s story with others.
Sources and Further Reading
Johns Hopkins Medicine — The Legacy of Henrietta Lacks: Information about her treatment, HeLa cells, and the ethical questions surrounding their use.
National Institutes of Health — The NIH–Lacks Family Agreement: Details about the agreement governing access to certain HeLa genomic data and protecting the family’s privacy.
World Health Organization — Honoring Henrietta Lacks: Recognition of her contribution to medical science and her family’s advocacy.
Rebecca Skloot — The Immortal Life of Henrietta Lacks (2010): An exploration of Henrietta’s life, her family, and the scientific and ethical history of HeLa cells.
Comments